Literature DB >> 10980596

Novel p53 splice site mutations in three families with Li-Fraumeni syndrome.

S J Verselis1, J G Rheinwald, J F Fraumeni, F P Li.   

Abstract

Germline mutations in the p53 tumor suppressor gene predispose to a variety of cancers in families with Li-Fraumeni syndrome. Most germline p53 mutations observed to date cause amino acid substitutions in the protein's central sequence-specific DNA binding domain. Outside this conserved core region, however, we found novel alterations in sequences that regulate precursor mRNA splicing in three Li-Fraumeni syndrome families. Two splice site mutations affected the consensus sequence at the splice donor sites of introns 1 and 9, and produced unstable variant transcripts in normal cells. A third mutation at the splice acceptor site of intron 9 generated splicing at a cryptic acceptor site in intron 9. These splice site alterations emphasize the need to examine both noncoding and untranslated regions of the p53 gene for germline mutations in Li-Fraumeni syndrome families. Oncogene (2000) 19, 4230 - 4235

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980596     DOI: 10.1038/sj.onc.1203758

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour.

Authors:  R H Scott; C A Stiller; L Walker; N Rahman
Journal:  J Med Genet       Date:  2006-05-11       Impact factor: 6.318

2.  Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.

Authors:  Xiao-mo Wu; Jing-geng Fu; Wang-zhong Ge; Jiang-yan Zhu; Jun-yong Wang; Wei Zhang; Wei Qian; Ke-ke Huo
Journal:  J Zhejiang Univ Sci B       Date:  2007-02       Impact factor: 3.066

3.  Organization and running of the first comprehensive hereditary cancer clinic in India.

Authors:  T Rajkumar; N Soumittra; E Vidubala; V Sridevi; V Mahajan; Sg Ramanan; S Vijaya
Journal:  Hered Cancer Clin Pract       Date:  2005-11-15       Impact factor: 2.857

Review 4.  Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Int J Cancer       Date:  2016-02-08       Impact factor: 7.396

5.  Biased exon/intron distribution of cryptic and de novo 3' splice sites.

Authors:  Jana Královicová; Mikkel B Christensen; Igor Vorechovský
Journal:  Nucleic Acids Res       Date:  2005-09-01       Impact factor: 16.971

6.  Aberrant 3' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization.

Authors:  Igor Vorechovský
Journal:  Nucleic Acids Res       Date:  2006-09-08       Impact factor: 16.971

7.  Serous Carcinoma of the Endometrium with Mesonephric-Like Differentiation Initially Misdiagnosed as Uterine Mesonephric-Like Adenocarcinoma: A Case Report with Emphasis on the Immunostaining and the Identification of Splice Site TP53 Mutation.

Authors:  Sangjoon Choi; Yoon Yang Jung; Hyun-Soo Kim
Journal:  Diagnostics (Basel)       Date:  2021-04-18

8.  Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.

Authors:  Anastasios Maniakas; Ying C Henderson; Hu Hei; Shaohua Peng; Yunyun Chen; Yujie Jiang; Shuangxi Ji; Maria Cardenas; Yulun Chiu; Diana Bell; Michelle D Williams; Marie-Claude Hofmann; Steve E Scherer; David A Wheeler; Naifa L Busaidy; Ramona Dadu; Jennifer R Wang; Maria E Cabanillas; Mark Zafereo; Faye M Johnson; Stephen Y Lai
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

9.  Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma.

Authors:  Ellen Heitzer; Sigurd Lax; Ingrid Lafer; Stephanie M Müller; Gunda Pristauz; Peter Ulz; Stephan Jahn; Christoph Högenauer; Edgar Petru; Michael R Speicher; Jochen B Geigl
Journal:  BMC Med Genet       Date:  2013-12-29       Impact factor: 2.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.